← Back to Company DatabaseVisit Website
Gritstone Bio
AI-powered immunology to develop cancer and infectious disease vaccines.
PublicEmeryville, CAFounded 2015
About
Gritstone Bio uses its proprietary EDGE AI platform to predict neoantigens that the immune system can target, enabling the development of personalized cancer immunotherapies. The company develops therapeutic vaccines that train the immune system to attack tumors by recognizing tumor-specific mutations. Its pipeline includes treatments for solid tumors using self-amplifying mRNA and adenoviral vectors.
Total Funding
$500MKey Product
GRANITE individualized neoantigen immunotherapyGeography
North AmericaKey Investors
The Column GroupVersant VenturesFrazier Healthcare Partners
Focus Areas
Treatment (Therapeutics)AI / Machine LearningDrug Discovery
Technology
ImmunotherapyAI / Machine Learning
Cancer Types
Pan-cancerLungColorectal
Last updated: Feb 4, 2026